From 1 December 2021, Australians with gastrointestinal stromal tumour will have access to a breakthrough new medicine listing on the Pharmaceutical Benefits Scheme (PBS).
The Morrison Government will list Qinlock®️ (ripretinib) on the PBS for the treatment of advanced gastrointestinal stromal tumour (GIST).
Without PBS subsidy, around 50 patients each year might pay more than $179,900 per course of treatment. Instead, they will pay a maximum of $41.30 per script or $6.60 with a concession card.
The Morrison Government’s commitment to ensuring that Australians can access affordable medicines, when they need them, remains rock solid.